CLINICAL TRIALS PROFILE FOR MEFOXIN

All Clinical Trials for MEFOXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00343317 ↗	Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women	Completed	Bristol-Myers Squibb	N/A	2003-02-01	Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.
NCT00343317 ↗	Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women	Completed	University of KwaZulu	N/A	2003-02-01	Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.

Clinical Trial Conditions for MEFOXIN

Condition Name

Condition Name for MEFOXIN
Intervention	Trials
Puerperal Sepsis	1

Condition MeSH

Condition MeSH for MEFOXIN
Intervention	Trials
Sepsis	1
HIV Seropositivity	1

Clinical Trial Locations for MEFOXIN

Trials by Country

Trials by Country for MEFOXIN
Location	Trials
South Africa	1

Clinical Trial Progress for MEFOXIN

Clinical Trial Phase

Clinical Trial Phase for MEFOXIN
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for MEFOXIN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MEFOXIN

Sponsor Name

Sponsor Name for MEFOXIN
Sponsor	Trials
Bristol-Myers Squibb	1
University of KwaZulu	1

Sponsor Type

Sponsor Type for MEFOXIN
Sponsor	Trials
Industry	1
Other	1